Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Clinical Oncology

• Publication date

  2010-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2009.25.4037PMID 20516432
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Trabectedin

  2012cited by this paper
• Global cancer statistics

  2011cited by this paper
• Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009

  2010cited by this paper
• Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.

  2009cited by this paper
• A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.

  2008cited by this paper
• Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.

  2007cited by this paper
• A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

  2007cited by this paper
• Chapter 11 – Epithelial Ovarian Cancer

  2007cited by this paper
• DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743).

  2006cited by this paper
• Hy's law: predicting serious hepatotoxicity

  2006cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials

  2006cited by this paper
• Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

  2006cited by this paper
• Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

  2005cited by this paper
• Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.

  2004cited by this paper
• Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies

  2003cited by this paper
• An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer.

  2003cited by this paper
• Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

  2003cited by this paper
• Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.

  2003cited by this paper
• Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells.

  2001cited by this paper
• Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

  1997cited by this paper
• The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

  1993cited by this paper
• Regression Models and Life-Tables

  1972cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Trabectedin maintenance therapy after liposomal doxorubicin plus trabectedin combination in patients with relapsed ovarian cancer: the randomized, phase II TRAMANT study.

  2025cites this paper
• GANNET53 Part II: A European Phase I/II Trial of the HSP90 inhibitor Ganetespib in high-grade Platinum-Resistant Ovarian Cancer - A Study of the GANNET53 consortium.

  2025cites this paper
• Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?

  2024cites this paper
• An update to experimental and clinical aspects of tumor-associated macrophages in cancer development: hopes and pitfalls

  2024cites this paper
• Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study

  2024cites this paper
• Can we learn from failures? A systematic review of phase III trials in platinum-resistant ovarian cancer.

  2024cites this paper
• Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial

  2024cites this paper
• Platinum- and Non-Platinum-Based Chemotherapy in Patients with Recurrent Platinum-Resistant Ovarian Cancer: A Review Article

  2024cites this paper
• In ovarian cancer maraviroc potentiates the antitumoral activity and further inhibits the formation of a tumor-promoting microenvironment by trabectedin.

  2024cites this paper
• The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial.

  2024cites this paper
• MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study

  2023cites this paper
• INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

  2023cites this paper
• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.

  2023cites this paper
• Combinational use of trabectedin and pegylated liposomal doxorubicin for recurrent ovarian cancer: a meta-analysis of phase III randomized controlled trials.

  2023cites this paper
• Efficacy of gemcitabine in combination with nanoparticle albumin‐bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review

  2023cites this paper
• Results of a Phase II Trial Testing the Resensitization With Trabectedin in Platinum-resistant Ovarian Cancer.

  2023cites this paper
• DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities

  2023cites this paper
• Antitumor Therapy Targeting the Tumor Microenvironment

  2023cites this paper
• Systemische Therapie der epithelialen serösen Ovarialkarzinome

  2023cites this paper
• Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review

  2022cites this paper
• Predicting Response to Anthracyclines in Ovarian Cancer

  2022cites this paper
• Trabectedin suppresses escape from therapy-induced senescence in tumor cells by interfering with glutamine metabolism.

  2022cites this paper
• Tratamiento médico de los cánceres epiteliales de ovario

  2022cites this paper
• Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives

  2022influential citation
• Pharmacotherapeutic treatment options for recurrent epithelial ovarian cancer

  2022cites this paper
• Traitement médical des cancers épithéliaux de l’ovaire

  2022cites this paper
• Malignant diseases of the ovary, fallopian tube, and peritoneum

  2022cites this paper
• A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis

  2022cites this paper
• Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study

  2022cites this paper
• Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research

  2022cites this paper
• Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).

  2022cites this paper
• Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma

  2022cites this paper
• From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds

  2022cites this paper
• The Systemic Treatment of Recurrent Ovarian Cancer revisited.

  2021cites this paper
• The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value.

  2021cites this paper
• A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer

  2021cites this paper
• Effect of molecular targeted agents in chemotherapy for treating platinum-resistant recurrent ovarian cancer

  2021cites this paper
• Medikamentöse Therapie des Ovarialkarzinoms

  2021cites this paper
• Ovarian Cancer: Primary Advanced and Recurrent Disease

  2021cites this paper
• Cancer of the ovary, fallopian tube, and peritoneum: 2021 update

  2021cites this paper
• Trabectedin-Related Heart Failure: Case Report and a Systematic Review of the Literature

  2021cites this paper
• Ovarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids

  2021cites this paper
• An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.

  2021cites this paper
• Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.

  2021cites this paper
• Real-world experience with trabectedin for the treatment of recurrent ovarian cancer

  2021influential citation
• Research progress in the treatment of partial platinum-sensitive recurrent ovarian cancer.

  2021cites this paper
• Trabectedin plus durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma (TRAMUNE): an open-label, multicenter phase Ib study.

  2021cites this paper
• Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores

  2021cites this paper
• Nanotechnology advances in ovarian cancer

  2021cites this paper
• Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer

  2021cites this paper
• Advances in Multidisciplinary Management of Skull Base Meningiomas

  2021cites this paper
• Advances in the application of nanotechnology in reducing cardiotoxicity induced by cancer chemotherapy.

  2021cites this paper
• A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum‐Sensitive Ovarian Cancer

  2020influential citation
• Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

  2020cites this paper
• Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m2 versus 40 mg/m2 in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial

  2020cites this paper
• DNA damaging agents in ovarian cancer

  2020cites this paper
• Carcinoma of the Ovaries and Fallopian Tubes

  2020cites this paper
• Treatment algorithm in patients with ovarian cancer

  2020cites this paper
• Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.

  2020cites this paper
• Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial

  2020cites this paper
• Current and future strategies for treatment of ovarian clear cell carcinoma

  2020cites this paper
• Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade

  2020cites this paper
• From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds

  2020cites this paper
• Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.

  2020cites this paper
• Cost-Effectiveness and Net Monetary Benefit of olaparib Maintenance Therapy Versus No Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-Mutated Ovarian Cancer in the Italian National Health Service.

  2020cites this paper
• Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.

  2020cites this paper
• A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.

  2020cites this paper
• A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics

  2020cites this paper
• GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer

  2020cites this paper
• Marine Ligands of the Pregnane X Receptor (PXR): An Overview

  2019cites this paper
• Marine Natural Products: A Source of Novel Anticancer Drugs

  2019cites this paper
• Cardiotoxicity with trabectedin in the treatment of advanced soft tissue sarcoma

  2019cites this paper
• Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer

  2019cites this paper
• Medikamentöse Therapie des Ovarialkarzinoms in der Primär- und Rezidivsituation

  2019cites this paper
• Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

  2019cites this paper
• Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.

  2019cites this paper
• Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer

  2019cites this paper
• Cardiac MRI: a Promising Diagnostic Tool to Detect Cancer Therapeutics–Related Cardiac Dysfunction

  2019cites this paper
• Chemotherapy Administration Sequencing: An Update on the Current Literature

  2019cites this paper
• Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer.

  2019cites this paper
• Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations

  2019influential citation
• Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis

  2019cites this paper
• Ovarian cancer relapse: From the latest scientific evidence to the best practice.

  2019cites this paper
• A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.

  2018cites this paper
• Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2018cites this paper
• Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors.

  2018cites this paper
• Trabectedin in Ovarian Cancer: is it now a Standard of Care?

  2018cites this paper
• Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κB

  2018cites this paper
• Cancer of the ovary, fallopian tube, and peritoneum

  2018cites this paper
• Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study

  2018cites this paper
• Oncologic orphan drugs approved in the EU – do clinical trial data correspond with real-world effectiveness?

  2018cites this paper
• Management and Treatment of Recurrent Epithelial Ovarian Cancer.

  2018cites this paper
• Management of relapsed ovarian cancer in routine clinical practice: a case study

  2018cites this paper
• Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis

  2018cites this paper
• Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design.

  2018cites this paper
• Chemotherapy for Primary and Recurrent Epithelial Ovarian Cancer

  2018cites this paper
• Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour

  2018cites this paper
• Surgical and Medical Management of Epithelial Ovarian Cancer

  2018cites this paper
• WITHDRAWN: Addition of targeted agents to chemotherapy for persistent or recurrent ovarian cancer: a meta-analysis of randomized controlled trials

  2018cites this paper
• Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line

  2018cites this paper